Market Signals Highlight Next Wave of Immunotherapy Growth (OSTX, IBRX)
AB Digital Inc (Tue, 16-Dec 3:16 PM ET)
ImmunityBio Reports Strong Long-Term Survival Data For Anktiva In Bladder Cancer Study
Benzinga (Tue, 16-Dec 1:20 PM ET)
Business Wire (Tue, 16-Dec 9:00 AM ET)
ImmunityBio Appoints Bruce Wendel to Board
TipRanks (Mon, 15-Dec 5:50 PM ET)
Piper Sandler Keeps Their Buy Rating on ImmunityBio (IBRX)
TipRanks (Mon, 15-Dec 7:15 AM ET)
ImmunityBio’s HCW9218 Study Completion: A Potential Game-Changer for Pancreatic Cancer Treatment
TipRanks (Sun, 14-Dec 11:32 AM ET)
ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy
Benzinga (Fri, 12-Dec 12:00 PM ET)
ImmunityBio’s Strategic and Regulatory Progress Fuels Buy Rating
TipRanks (Fri, 12-Dec 11:55 AM ET)
ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week
Seeking Alpha News (Fri, 12-Dec 10:45 AM ET)
ImmunityBio, Moderna among winners of EU drug recommendations this week
Seeking Alpha News (Fri, 12-Dec 10:45 AM ET)
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Immunitybio trades on the NASDAQ stock market under the symbol IBRX.
As of December 16, 2025, IBRX stock price declined to $2.16 with 15,811,083 million shares trading.
IBRX has a beta of 2.18, meaning it tends to be more sensitive to market movements. IBRX has a correlation of 0.21 to the broad based SPY ETF.
IBRX has a market cap of $2.13 billion. This is considered a Mid Cap stock.
Last quarter Immunitybio reported $32 million in Revenue and -$.07 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.03.
In the last 3 years, IBRX traded as high as $10.53 and as low as $1.21.
The top ETF exchange traded funds that IBRX belongs to (by Net Assets): VTI, VB, XBI, IWM, VBK.
IBRX has underperformed the market in the last year with a price return of -24.7% while the SPY ETF gained +13.6%. IBRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.2% and -6.1%, respectively, while the SPY returned +3.0% and -0.2%, respectively.
IBRX support price is $2.10 and resistance is $2.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBRX shares will trade within this expected range on the day.